Did the critics of Acadia Pharmaceuticals — and I’m very much included in that group — underestimate the efficacy of the drugmaker’s antipsychotic medicine Nuplazid? Or, did we fail to appreciate Acadia’s cleverness in designing a clinical trial for a mediocre medicine that could still deliver a positive result?
Maybe I’m stubborn, but I lean towards the latter. Still, there is no denying that Monday is a very good day for Acadia and those who believe in Nuplazid’s potential to be a more widely used antipsychotic drug. A Phase 3 clinical trial investigating Nuplazid as a treatment for dementia-related psychosis was stopped early for positive efficacy, Acadia announced.